-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Huntington's disease (HD) is a degenerative disease of the central nervous system, which is caused by CAG repeat expansion (>35 CAGs) in the Huntingtin gene.
The loss of neurons in the brain leads to progressive motor abnormalities, cognitive decline and eventually death.
Tension diagnosis
In this way, Branduff McAllister and others of Cardiff University in the United Kingdom used the HD Clinical Characteristics Questionnaire (HD -CCQ) Collected retrospective data on the prevalence and time of 8 types of motor, cognitive and psychiatric symptoms in HD patients.
These data come from the European REGISTRY study, which analyzed the clinical characteristics of 6,316 HD patients from 161 locations in 17 countries.
They found that as the age of onset increases, the initial manifestations of HD are more likely to be motor symptoms, and less psychiatric symptoms, and have nothing to do with the length of the pathogenic CAG repeat.
As the age of onset increases, the initial manifestations of HD are more and more likely to be motor symptoms, and less psychiatric symptoms, and have nothing to do with the length of the pathogenic CAG repeat.
42.
This pooled study of thousands of people revealed that among HD gene carriers, mental and cognitive symptoms are common, and they are functionally debilitating.
In HD gene carriers, mental and cognitive symptoms are common, and they are functionally debilitating.
neurology.
org/content/early/2021/03/25/WNL.
0000000000011893" target="_blank" rel="noopener">Impact of Psychiatric and the Timing, Cognitive, and Motor Abnormalities in Huntington Disease
neurology.
org/content/early/2021/03/25/WNL.
0000000000011893" target="_blank" rel="noopener">Branduff McAllister, James Gusella F.
, G.
et Al.
neurology.
org/content/early/2021/03/25/WNL.
0000000000011893" target="_blank" rel="noopener">.
Neurology-Mar 2021, 10.
1212 / WNL.
0000000000011893; the DOI: 10.
1212 / WNL.
0000000000011893
in this message